Key Market Highlights The global GLP-1 analogues market was valued at US$ 51.6 Billion in 2024 The market is expected to reach US$ 211.8 Billion by 2035 The industry is forecast to expand at a CAGR of 13.7% during 2025-2035 North America accounted for the largest market share of 68.4% in 2024 The Subcutaneous route of administration segment held 78.2% market share in 2024 Major industry participants include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, and AstraZeneca Rising Type 2 Diabetes Cases Accelerating Market Growth The growing prevalence of type 2 diabetes remains one of the most significant growth drivers for the GLP-1 analogues market
This includes those in the Program of All-inclusive Care for the Elderly (PACE), available in some states, that allows people who need nursing home care to remain at home
This interaction sends signals to the brain suggesting fullness, subsequently decreasing the individuals appetite, leading to a reduction in food intake and aiding in weight loss
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Ros membership is $39 the first month, then $149/month ongoing (or $74/month on the annual prepay)
May 23, 2012
